Receive News & Ratings for TG Therapeutics Inc. Daily

Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

TG Therapeutics (TGTX) Given Daily Media Impact Score of 0.15

Media coverage about TG Therapeutics (NASDAQ:TGTX) has been trending somewhat positive recently, according to Accern. The research group identifies positive and negative news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. TG Therapeutics earned a news sentiment score of 0.15 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 46.8627635145789 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Receive News & Ratings for TG Therapeutics Inc. Daily

Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Here are some of the media stories that may have effected Accern’s analysis:

A number of equities research analysts recently commented on the company. FBR & Co reiterated a “buy” rating on shares of TG Therapeutics in a research report on Thursday, May 18th. Zacks Investment Research lowered TG Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, August 4th. BidaskClub upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, July 24th. ValuEngine upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $23.00 target price on shares of TG Therapeutics in a research report on Monday, June 5th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $25.40.

TG Therapeutics (NASDAQ TGTX) opened at 11.95 on Friday. TG Therapeutics has a 52 week low of $4.10 and a 52 week high of $15.35. The firm’s market capitalization is $744.60 million. The stock’s 50 day moving average price is $11.05 and its 200 day moving average price is $10.43.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.01. TG Therapeutics had a negative return on equity of 154.02% and a negative net margin of 68,806.59%. The business had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.04 million. On average, equities analysts expect that TG Therapeutics will post ($1.84) EPS for the current year.

In related news, CFO Sean A. Power sold 59,976 shares of the stock in a transaction that occurred on Monday, June 19th. The stock was sold at an average price of $11.09, for a total value of $665,133.84. Following the completion of the transaction, the chief financial officer now directly owns 477,464 shares of the company’s stock, valued at approximately $5,295,075.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 16.70% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “[[title]]” was first reported by [[site]] and is owned by of [[site]]. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at [[permalink]].

TG Therapeutics Company Profile

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.